Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
8.20
+0.25 (3.14%)
Mar 11, 2025, 4:00 PM EST - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 23.83, with a low estimate of 13 and a high estimate of 47. The average target predicts an increase of 190.61% from the current stock price of 8.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +192.68% | Feb 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +168.29% | Feb 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $47 | Strong Buy | Maintains | $35 → $47 | +473.17% | Feb 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 | Strong Buy | Maintains | $35 | +326.83% | Jan 8, 2025 |
| Needham | Needham | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +168.29% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
18.61M
from 8.78M
Increased by 111.92%
Revenue Next Year
32.02M
from 18.61M
Increased by 72.11%
EPS This Year
-2.06
from -2.38
EPS Next Year
-2.17
from -2.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 19.8M | 83.0M | 73.5M | |||
| Avg | 18.6M | 32.0M | 25.7M | |||
| Low | 17.1M | 5.9M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 126.0% | 345.8% | 129.5% | |||
| Avg | 111.9% | 72.1% | -19.8% | |||
| Low | 94.7% | -68.4% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.08 | -0.97 | -2.44 | |||
| Avg | -2.06 | -2.17 | -2.72 | |||
| Low | -2.04 | -2.70 | -3.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.